tetano
Editor, Senior Moderator
R I Med J (2013)
. 2022 Jun 1;105(5):41-45.
Multisystem Inflammatory Syndrome in an Adolescent Following SARS-CoV-2 Exposure Despite Three Doses of a COVID-19 Vaccine
Anurag Ratan Goel[SUP] 1 [/SUP], Silvia S Chiang[SUP] 2 [/SUP], Osama Ibrahim[SUP] 2 [/SUP], Ali Yalcindag[SUP] 3 [/SUP]
Affiliations
Abstract
The multisystem inflammatory syndrome in children (MIS-C) is a known complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the pediatric population. Recent studies have demonstrated high efficacy of a two-dose vaccine series in preventing MIS-C among adolescents. To date, such studies have only included children exposed to SARS-CoV-2 prior to the emergence of the Omicron variant (B.1.1.529). We report a case of an adolescent who received three doses of a vaccine yet developed MIS-C following known exposure to SARS-CoV-2. Given the uncertainty in whether current vaccines offer as much protection against MIS-C due to the Omicron variant or any potential new variants as they have for older variants, pediatric providers should maintain a high index of suspicion for MIS-C regardless of vaccination status.
Keywords: COVID-19; MIS-C; Omicron; SARS-CoV-2; multisystem inflammatory syndrome in children.
. 2022 Jun 1;105(5):41-45.
Multisystem Inflammatory Syndrome in an Adolescent Following SARS-CoV-2 Exposure Despite Three Doses of a COVID-19 Vaccine
Anurag Ratan Goel[SUP] 1 [/SUP], Silvia S Chiang[SUP] 2 [/SUP], Osama Ibrahim[SUP] 2 [/SUP], Ali Yalcindag[SUP] 3 [/SUP]
Affiliations
- PMID: 35617041
Abstract
The multisystem inflammatory syndrome in children (MIS-C) is a known complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the pediatric population. Recent studies have demonstrated high efficacy of a two-dose vaccine series in preventing MIS-C among adolescents. To date, such studies have only included children exposed to SARS-CoV-2 prior to the emergence of the Omicron variant (B.1.1.529). We report a case of an adolescent who received three doses of a vaccine yet developed MIS-C following known exposure to SARS-CoV-2. Given the uncertainty in whether current vaccines offer as much protection against MIS-C due to the Omicron variant or any potential new variants as they have for older variants, pediatric providers should maintain a high index of suspicion for MIS-C regardless of vaccination status.
Keywords: COVID-19; MIS-C; Omicron; SARS-CoV-2; multisystem inflammatory syndrome in children.